Billiontoone (NASDAQ:BLLN) Insider Sells $880,000.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $110.00, for a total transaction of $880,000.00. Following the completion of the transaction, the insider owned 208,000 shares of the company’s stock, valued at $22,880,000. This trade represents a 3.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total transaction of $785,760.00.

Billiontoone Trading Up 5.3%

Shares of NASDAQ BLLN traded up $5.93 during midday trading on Friday, hitting $118.17. 962,346 shares of the company traded hands, compared to its average volume of 476,253. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $138.70. The firm has a market cap of $5.44 billion and a P/E ratio of 214.85. The stock has a 50-day moving average price of $91.82 and a 200 day moving average price of $87.11. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. The business’s quarterly revenue was up 83.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.39) earnings per share. As a group, analysts expect that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BLLN shares. JPMorgan Chase & Co. lifted their price target on Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Guggenheim upped their target price on shares of Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Wells Fargo & Company decreased their price target on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. Finally, Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $125.29.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Adams Street Partners LLC purchased a new position in Billiontoone during the fourth quarter valued at $140,063,000. Baillie Gifford & Co. purchased a new stake in shares of Billiontoone in the fourth quarter worth $103,786,000. Price T Rowe Associates Inc. MD bought a new position in shares of Billiontoone during the fourth quarter valued at $39,717,000. JPMorgan Chase & Co. bought a new position in shares of Billiontoone during the fourth quarter valued at $32,078,000. Finally, Wasatch Advisors LP purchased a new position in shares of Billiontoone in the 1st quarter worth about $29,179,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.